217 related articles for article (PubMed ID: 36085201)
1. Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors.
Rivas EI; Linares J; Zwick M; Gómez-Llonin A; Guiu M; Labernadie A; Badia-Ramentol J; Lladó A; Bardia L; Pérez-Núñez I; Martínez-Ciarpaglini C; Tarazona N; Sallent-Aragay A; Garrido M; Celià-Terrassa T; Burgués O; Gomis RR; Albanell J; Calon A
Nat Commun; 2022 Sep; 13(1):5310. PubMed ID: 36085201
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer.
Luque M; Sanz-Álvarez M; Santamaría A; Zazo S; Cristóbal I; de la Fuente L; Mínguez P; Eroles P; Rovira A; Albanell J; Madoz-Gúrpide J; Rojo F
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948097
[TBL] [Abstract][Full Text] [Related]
3. PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity.
Du R; Zhang X; Lu X; Ma X; Guo X; Shi C; Ren X; Ma X; He Y; Gao Y; Liu Y
Drug Resist Updat; 2023 May; 68():100947. PubMed ID: 36812747
[TBL] [Abstract][Full Text] [Related]
4. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
[TBL] [Abstract][Full Text] [Related]
5. Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer.
Sonnenblick A; Salmon-Divon M; Salgado R; Dvash E; Pondé N; Zahavi T; Salmon A; Loibl S; Denkert C; Joensuu H; Ameye L; Van den Eynden G; Kellokumpu-Lehtinen PL; Azaria A; Loi S; Michiels S; Richard F; Sotiriou C
Int J Cancer; 2020 Jul; 147(1):266-276. PubMed ID: 31904863
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
7. A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM).
Wege AK; Kirchhammer N; Kazandjian LV; Prassl S; Brandt M; Piendl G; Ortmann O; Fischer S; Brockhoff G
J Transl Med; 2020 Aug; 18(1):316. PubMed ID: 32799890
[TBL] [Abstract][Full Text] [Related]
8. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.
Fernández-Nogueira P; Mancino M; Fuster G; López-Plana A; Jauregui P; Almendro V; Enreig E; Menéndez S; Rojo F; Noguera-Castells A; Bill A; Gaither LA; Serrano L; Recalde-Percaz L; Moragas N; Alonso R; Ametller E; Rovira A; Lluch A; Albanell J; Gascon P; Bragado P
Clin Cancer Res; 2020 Mar; 26(6):1432-1448. PubMed ID: 31699826
[TBL] [Abstract][Full Text] [Related]
10. Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models.
Gonzalez-Alonso P; Cristobal I; Zazo S; Martin-Aparicio E; Chamizo C; Madoz-Gurpide J; Rovira A; Eroles P; Lluch A; Albanell J; Rojo F
Curr Med Chem; 2018; 25(17):1976-1998. PubMed ID: 27993109
[TBL] [Abstract][Full Text] [Related]
11. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
Hamilton EP; Kaklamani V; Falkson C; Vidal GA; Ward PJ; Patre M; Chui SY; Rotmensch J; Gupta K; Molinero L; Li Y; Emens LA
Clin Breast Cancer; 2021 Dec; 21(6):539-551. PubMed ID: 34154926
[TBL] [Abstract][Full Text] [Related]
12. Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab.
Zheng G; Guo Z; Li W; Xi W; Zuo B; Zhang R; Wen W; Yang AG; Jia L
Signal Transduct Target Ther; 2021 Jun; 6(1):236. PubMed ID: 34158475
[TBL] [Abstract][Full Text] [Related]
13. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem cell-targeted therapeutic approaches for overcoming trastuzumab resistance in HER2-positive breast cancer.
Qiu Y; Yang L; Liu H; Luo X
Stem Cells; 2021 Sep; 39(9):1125-1136. PubMed ID: 33837587
[TBL] [Abstract][Full Text] [Related]
15. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
16. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer.
Bonneau C; Eliès A; Kieffer Y; Bourachot B; Ladoire S; Pelon F; Hequet D; Guinebretière JM; Blanchet C; Vincent-Salomon A; Rouzier R; Mechta-Grigoriou F
Breast Cancer Res; 2020 Jul; 22(1):76. PubMed ID: 32665033
[TBL] [Abstract][Full Text] [Related]
17. Dissecting Effects of Anti-cancer Drugs and Cancer-Associated Fibroblasts by On-Chip Reconstitution of Immunocompetent Tumor Microenvironments.
Nguyen M; De Ninno A; Mencattini A; Mermet-Meillon F; Fornabaio G; Evans SS; Cossutta M; Khira Y; Han W; Sirven P; Pelon F; Di Giuseppe D; Bertani FR; Gerardino A; Yamada A; Descroix S; Soumelis V; Mechta-Grigoriou F; Zalcman G; Camonis J; Martinelli E; Businaro L; Parrini MC
Cell Rep; 2018 Dec; 25(13):3884-3893.e3. PubMed ID: 30590056
[TBL] [Abstract][Full Text] [Related]
18. Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer.
Hori A; Shimoda M; Naoi Y; Kagara N; Tanei T; Miyake T; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res; 2019 Aug; 21(1):88. PubMed ID: 31387614
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
[TBL] [Abstract][Full Text] [Related]
20. The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.
Janiszewska M; Stein S; Metzger Filho O; Eng J; Kingston NL; Harper NW; Rye IH; Alečković M; Trinh A; Murphy KC; Marangoni E; Cristea S; Oakes B; Winer EP; Krop IE; Russnes HG; Spellman PT; Bucher E; Hu Z; Chin K; Gray JW; Michor F; Polyak K
JCI Insight; 2021 Jun; 6(11):. PubMed ID: 33886505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]